NCT05490446Phase 2Active not recruiting

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Study sponsor: Agios Pharmaceuticals, Inc. · AGIO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-03-17Actual
Enrollment · participants87Actual
Source updated2026-09-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Mar 2026. After: 17 Mar 2026.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 82 participants (planned). After: 87 participants (actual).

Primary completion date changed

Before: Nov 2025. After: Mar 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview